CVRx Names John Landry CFO, Succeeding John Oasheim Effective October 12

CVRx, Inc. (CVRX) announced Monday the appointment of John Landry as Chief Financial Officer, effective October 12, 2026. He succeeds John Oasheim, who will remain with the commercial-stage medical device company through a transition period. Landry's appointment follows the standard executive succession process, with Oasheim staying on temporarily to ensure continuity in the finance function. The company did not disclose additional terms of the transition. CVRx develops implantable neuromodulation devices for patients with cardiovascular disease. The Minnesota-based company went public in 2021 and trades on the Nasdaq under the ticker CVRX.